ALLO - Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential
- Phase I trials mean more usual for Cellectis.
- Cellectis is pursuing low-hanging fruit indications.
- New pipeline programs and their IP position offer upside on top of their CAR-T programs.
For further details see:
Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential